Therapeutic Targets of Monoclonal Antibodies Used in the Treatment of Cancer: Current and Emerging
| Primer Autor |
Effer, Brian
|
| Co-autores |
Perez, Isabela
Ulloa, Daniel
Mayer, Carolyn
Munoz, Francisca
Bustos, Diego
Rojas, Claudio
Manterola, Carlos
Vergara-Gomez, Luis
Dappolonnio, Camila
Weber, Helga
Leal, Pamela
|
| Título |
Therapeutic Targets of Monoclonal Antibodies Used in the Treatment of Cancer: Current and Emerging
|
| Editorial |
MDPI
|
| Revista |
BIOMEDICINES
|
| Lenguaje |
en
|
| Resumen |
Cancer is one of the leading global causes of death and disease, and treatment options are constantly evolving. In this sense, the use of monoclonal antibodies (mAbs) in immunotherapy has been considered a fundamental aspect of modern cancer therapy. In order to avoid collateral damage, it is indispensable to identify specific molecular targets or biomarkers of therapy and/or diagnosis (theragnostic) when designing an appropriate immunotherapeutic regimen for any type of cancer. Furthermore, it is important to understand the currently employed mAbs in immunotherapy and their mechanisms of action in combating cancer. To achieve this, a comprehensive understanding of the biology of cancer cell antigens, domains, and functions is necessary, including both those presently utilized and those emerging as potential targets for the design of new mAbs in cancer treatment. This review aims to provide a description of the therapeutic targets utilized in cancer immunotherapy over the past 5 years, as well as emerging targets that hold promise as potential therapeutic options in the application of mAbs for immunotherapy. Additionally, the review explores the mechanisms of actin of the currently employed mAbs in immunotherapy.
|
| Fecha Publicación |
2023
|
| Tipo de Recurso |
artículo de revisión
|
| doi |
10.3390/biomedicines11072086
|
| Formato Recurso |
PDF
|
| Palabras Claves |
cancer
immunotherapy
monoclonal antibody
therapeutic targets
|
| Ubicación del archivo | |
| Categoría OCDE |
Bioquímica y biología molecular
Investigación y medicina experimental
Farmacología y farmacia
|
| Materias |
cáncer
inmunoterapia
anticuerpo monoclonal
dianas terapéuticas
|
| Identificador del recurso (Mandatado-único) |
artículo de revisión
|
| Versión del recurso (Recomendado-único) |
versión publicada
|
| License |
CC BY 4.0
|
| Condición de la licencia (Recomendado-repetible) |
CC BY 4.0
|
| Derechos de acceso |
acceso abierto
|
| Access Rights |
acceso abierto
|
| Id de Web of Science |
WOS:001037956800001
|
| Tipo de ruta |
verde# dorado
|
| Categoría WOS |
Bioquímica y biología molecular
Investigación y medicina experimental
Farmacología y farmacia
|
| Referencia del Financiador (Mandatado si es aplicable-repetible) |
ANID-FONDECYT 3210142
ANID-FONDECYT 11180987
ANID-FONDECYT 1201734.
|
cienciaabierta.ufro.cl
ciencia.abierta@ufrontera.cl